As private equity consolidates autism therapy, a century-old doctrine limiting who may own a clinical practice is resurfacing as a check, and New York is the test case.
Key Takeaways
Non-clinicians are making clinical calls. As investors buy up ABA providers, business executives increasingly occupy clinical decision-making roles and set billable-hour targets that can override clinical judgment. That friction is drawing a legal response.
An old doctrine is the lever. In states that license behavior analysts and enforce the corporate practice of medicine, an ABA practice organized as a professional entity has to be owned by licensed clinicians, not outside investors. New York is the clearest example.
Private equity has a workaround. Deals in strict states run through a clinician-owned professional corporation paired with an investor-owned management company, a structure borrowed from dermatology and dental roll-ups. Whether it holds up under scrutiny is contested.
Licensure is spreading, and so is the fight. Behavior analysts are now licensed in roughly 39 states and the District of Columbia, and more states are weighing owner-must-be-a-clinician rules. The result will shape who controls autism therapy as consolidation runs on.
Nearly every clinical complaint about the corporatization of autism therapy circles back to the same place: the person setting the priorities often has never run a session. “When an investor purchases these agencies, they may put their own people in clinical and administrative decision-making roles, and they’re not behavior analysts,” Dr. Gina Green, a past president of the California Association for Behavior Analysis and now its public policy consultant, said in an interview with Acuity. “They’re responsible to the ownership and the investors, and they may be looking at things like billable hours and profit margins.” What she is describing, visible across the largest multi-state providers, has begun to collide with a piece of law older than most of the profession, one that in some states decides who is even allowed to own an ABA company.
When the boss is not a clinician
Green’s worry is not that executives mean harm but that clinical and financial authority end up in the wrong hands. A junior analyst who reports to an owner focused on utilization is poorly placed to hold a line. “If the behavior analysts in those positions are themselves not very experienced, it may be very difficult for them to push back against those kinds of pressures and demands from the front office,” she said.
The remedy she sees forming is borrowed from older professions. “In some states, for certain kinds of agencies, mainly in health care, there are laws that require the owner to be licensed,” Green said. “If you’re going to have an agency that provides clinical psychology services, there may be a law that says at least one owner must be a licensed clinical psychologist.” Rules requiring ABA agencies to be owned by licensed behavior analysts, she added, are probably in part a reaction to the corporate ownership that has spread through autism services. Green was candid that she has no data on how many states have such rules, so the legal specifics that follow come from the statutes and regulators, not from her.
It helps to keep two things apart. Licensing a behavior analyst governs an individual’s right to practice; on its own it says nothing about who may own the company that employs them. Ownership lives in a separate layer of law, the professional-entity and corporate-practice rules that decide which businesses may deliver a licensed service. That layer bites only where a state both licenses behavior analysts and applies corporate-practice restrictions to the profession, which is why the map looks so uneven.
New York’s rule: clinicians only
New York is the cleanest illustration, because it does two things at once: it licenses behavior analysts, and it runs one of the strictest corporate-practice regimes in the country. The state created the Licensed Behavior Analyst and Certified Behavior Analyst Assistant credentials through Article 167 of the Education Law, enacted in 2013 and amended in 2014. That made ABA a licensed profession, which pulls it under New York’s professional-entity rules.
The State Education Department is explicit about what that means for ownership. Licensed behavior analysts may form a professional corporation or a professional limited liability company, but membership in those entities, in the department’s words, is restricted to persons licensed in the same profession. Business Corporation Law Section 1507 lets a professional corporation issue shares only to individuals licensed to practice the profession the corporation is authorized to practice. On top of that sits the state’s century-old prohibition on the corporate practice of medicine, drawn from the Education Law, under which offering a licensed profession without a license is a felony and splitting fees with unlicensed parties is misconduct. The result is stark: in New York, an ABA practice set up as a professional entity has to be clinician-owned, and an outside investor cannot simply buy it.
How private equity structures around it
Strict ownership rules have never kept investors out of medicine, and they are unlikely to keep them out of ABA. The workaround, refined over years of dermatology, dental, and physician deals, is the management services organization. A clinician-owned professional corporation employs the licensed staff and holds the clinical work; a separate, investor-owned company handles everything else, the billing, the hiring of non-clinical staff, the technology and the real estate, under a long-term management agreement. A stock transfer restriction agreement typically lets the management company control who inherits the clinician-owner’s shares. It is the same architecture that now underpins ABA deal structuring and valuation.
The model is legal, but not bulletproof. Regulators and courts have warned that an arrangement handing the management company too much say over clinical decisions, or paying it a straight percentage of practice revenue, can trip the corporate-practice and fee-splitting lines. Health-care lawyers advise keeping the management fee tied to the actual cost of services and leaving clinical decisions with the professional entity, which is the boundary a cost-focused owner has every incentive to blur. Roughly 33 states enforce some version of the doctrine, with New York, California, Texas, and North Carolina among the strictest, so exposure swings sharply depending on where a provider operates.
The unevenness runs both ways. California, the largest ABA market in the country and among the toughest corporate-practice states, does not currently license behavior analysts at all, which muddies whether the ownership rule even reaches ABA there. Meanwhile a broader wave of state action against private-equity influence in health care, including new laws requiring notice or review of health-care deals, is tightening the ground under exactly the structures ABA has adopted. A doctrine that lay dormant for autism services while the field was unregulated is turning into live terrain as licensure and payer infrastructure spread across the map.
For operators, the consequences are concrete. A deal that is clean in one state can be vulnerable in another, and the ownership questions that surface in Medicaid oversight and state reimbursement overhauls now surface in diligence too. For the families and regulators worried that money is steering care, ownership law is one of the few levers that reaches the problem at the root, by putting a licensed clinician, at least on paper, back in charge of the practice. Whether that control turns out to be real or nominal, in New York and everywhere the management-company model travels, is what the next round of enforcement will decide.
